Immunotherapies
have evolved
Harnessing more of the immune system for better cancer outcomes
Latest News

We are hiring! University: Commercialisation Manager – Life Sciences. Great opportunity to join our team at Monash Innovation commercialising some of the amazing research ⁦@MonashUni⁩ ⁦@Monash_FMNHS⁩ ⁦@MIPS_Australia⁩ ⁦@MonashBDI⁩ https://www.linkedin.com/jobs/view/2649149480

More recently, clinician scientists @Kaufm020 (PMID: 32531207) and @lab_rezvani @may_daher (PMID: 32902645) have validated CISH as a checkpoint in human NK cells and CAR NK cells thus pushing this discovery closer to the clinic to benefit cancer patients

I fondly remember presenting this CISH KO human NK cell data alongside @BioNTech_Group founder Uğur Şahin at the CIMT 2017 in Mainz and the excitement around potential NK cell therapies for cancer.

Load More...
 
Discover oNKo-innate
With our deep understanding of Natural Killer (NK) cells, we aim to be the first to master NK cell biology and therapeutically harness the cancer-fighting abilities of these remarkable white blood cells.
Learn more
OUR APPROACH
Using powerful genomic approaches, we screen primary immune cells and cancer cells to understand their interaction within a tumor.
Learn more
lab1-webRes
o o
o
THE TEAM
We are driven by the challenge of engaging the immune system to fight cancer, and focused on delivering the first truly effective NK cell immunotherapies.
Find out who we are